Impact of renal insufficiency on mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention by Sabroe, Jonas Emil et al.
Sabroe et al. BMC Cardiovascular Disorders 2014, 14:15
http://www.biomedcentral.com/1471-2261/14/15RESEARCH ARTICLE Open AccessImpact of renal insufficiency on mortality in
patients with ST-segment elevation myocardial
infarction treated with primary percutaneous
coronary intervention
Jonas Emil Sabroe, Per Thayssen, Lisbeth Antonsen, Mikkel Hougaard, Knud Nørregaard Hansen
and Lisette Okkels Jensen*Abstract
Background: Chronic kidney disease is associated with increased risk of mortality. We examined the impact of
moderate and severe renal insufficiency (RI) on short- and long-term mortality among unselected patients with
ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).
Methods: From January 1, 2002 to December 31, 2010 all patients with STEMI treated with primary PCI were identified.
The hazard ratio (HR) for death was estimated using a Cox regression model, controlling for potential confounders. RI was
defined as creatinine clearance (CrCl) < 60 mL/min (moderate RI: CrCl ≤30 < 60 mL/min and severe RI: CrCl < 30 mL/min).
Results: The study cohort consisted of 4,116 patients of whom 898 (21.8%) had RI and 3,218 (78.2%) had a
CrCl ≥ 60 mL/min. Compared to patients without RI, patients with RI were older, more often female and more
likely to have diabetes mellitus, hypertension and to present with a higher Killip class.
Among patients with a preserved kidney function and patients with RI, 30-day all-cause mortality was 3.5% vs.
20.9% (log-rank p < 0.001); 1-year all-cause mortality was 5.7% vs. 29.4% (log-rank p < 0.001); 5-year all-cause mortality
was 13.4% vs. 47.4% (log-rank p < 0.001). Moderate and severe RI were associated with higher 1-year mortality compared
to patients with a preserved renal function (CrCl ≤30 < 60 mL/min: adjusted HR 2.71 [95% CI 2.09-3.51], p < 0.001), and
(CrCl < 30 mL/min: adjusted HR 7.09 [4.82-10.44], p < 0.001).
Conclusion: In unselected STEMI patients treated with primary PCI, moderate and severe RI were associated with
increased risk of mortality.
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Cardiovascular disease (CVD) is a leading cause of death
in the western countries [1]. Studies have shown that
impaired renal function is to be considered a risk factor
in relation to CVD and patients suffering from renal dis-
ease have a higher risk of CVD [2-4]. Also, chronic kid-
ney disease (CKD) is found to be strongly associated
with an increased risk of myocardial infarction (MI) and
CVD mortality [5,6]. Furthermore, CKD is found to
affect patients on a global scale and with an increasing* Correspondence: okkels@dadlnet.dk
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reproduction in any medium, provided the orincidence and prevalence [7]. After ST-segment eleva-
tion MI (STEMI) and non-STEMI the mortality has
been reported to be significantly higher among patients
with renal disease compared to patients with preserved
renal function [8-10]. Today primary PCI is the recom-
mended reperfusion strategy when treating patients with
STEMI, which also applies to STEMI patients with renal
dysfunction [11]. Limited data are available on the out-
come after primary PCI in STEMI patients with RI, be-
cause they have been underrepresented in randomized
trials, as renal failure is a commonly used exclusion
criterion [12].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Registry (WDHR) were used in order to assess the im-
pact of moderate and severe renal insufficiency (RI) on
short- and long-term mortality among unselected STEMI
patients treated with primary PCI. Primary PCI has been
the recommended treatment for STEMI after publication
of the results of the DANish trial in Acute Myocardial
Infarction-2 (DANAMI-2) in 2003 [13].
Methods
Setting and design
The study was conducted using WDHR for patients
treated at Odense University Hospital. A detailed de-
scription of the databases has been reported previously
[14]. The study was a registry study and ethical approval
was not required.
Patients and procedures
To be eligible for primary PCI, patients must meet the fol-
lowing criteria: 1) symptoms present less than 12 hours
from onset of pain to time of catheterization, and 2) ST-
segment elevation (at least 0.1 mV in two or more
standard leads or at least 0.2 mV in two or more con-
tiguous pre-cordial leads) or a new left bundle-branch
block (LBBB). Patient with cardiogenic shock were not
excluded. We used the WDHR to identify all primary
PCIs performed from January 1, 2002 through Decem-
ber 31, 2010. Drug eluting stent (DES), bare metal
stent (BMS), glycoprotein IIb/IIIa receptor blocker,
and intra-aortic balloon pump was administered at the
operator’s discretion. All patients received antiplatelet
regimen including a bolus of 10,000 IU heparin, life-
long acetylsalicylic acid (75–150 mg once daily), and
clopidogrel with a loading dose of 300 mg followed by
maintenance with 75 mg daily. The recommended dur-
ation of clopidogrel treatment was 3 to 12 months
until November 2002 and 12 months thereafter.
Blood samples were taken from the arterial sheath be-
fore the first contrast injection and serum creatinine -
concentration was assessed in the hospital laboratory.
Estimation of renal function is commonly based on esti-
mated creatinine clearance (CrCl). Different methods are
available. Studies have shown that The Modification of
Diet in Renal Disease (MDRD) formula gives a reliable
estimated CrCl [15-17], representing estimated glomeru-
lar filtration ratio (eGFR). Therefore the MDRD formula
was used in this study: eGFR = estimated CrCl = 186 ×
standardized S-Cr-1.154 × age-0.203 × 0.742 [if female]
[18]. The unit of this equation is expressed as mL/min
per 1.73 m2 body surface area. An eGFR less than
60 mL/min per 1.73 m2 was considered equivalent to
RI. Based on eGFR the study population was divided
into three groups, a group with eGFR ≥ 60 mL/min per
1.73 m2, a group with moderate RI: CrCl ≤30 < 60 mL/minper 1.73 m2, and a group with severe RI: CreaCl <
30 mL/min per 1.73 m2. This classification of patients
into different stages of CKD is identical with those uni-
versally endorsed and based on the National Kidney
Foundation data [7] where patients with an eGFR ≥
60 mL/min per 1.73 m2 is STAGE I/II, patients with
30 ≤ eGFR < 60 mL/min per 1.73 m2 are in STAGE III,
and patients with eGFR < 30 mL/min per 1.73 m2 are
in STAGE IV/V.
Endpoints
Primary end-point of the study was all cause-mortality
rate. Data on mortality were obtained from the Danish
Civil Registration System [19,20], which has kept elec-
tronic records on the gender, date of birth, changes in
address, date of emigration, and changes in vital status
of the entire Danish population since 1968.
Statistics
Continuous variables were presented as medians with in-
ter quartile range (IQR 25th, 75th) or mean ± 1 standard
deviations (SD). Medians were compared using the
Mann–Whitney U test, and means were compared using
the unpaired t test. Categorical variables were presented
as numbers and percentages. Distributions of categorical
variables were compared using the Chi-square test.
We counted end-point events that occurred during the
follow-up period and compared rates for the two groups
(CrCl ≥60 mL/min per 1.73 m2 vs. CrCl <60 mL/min per
1.73 m2). Follow-up began on the date of primary PCI
procedure and continued until date of death, December
31, 2010 or after 5 years follow-up (to ensure at least 10%
of the study population at risk), whichever came first.
Kaplan-Meier curves for all-cause mortality according to
kidney function (CrCl ≥ 60 mL/min per 1.73 m2, CrCl
≤30 < 60 mL/min per 1.73 m2 and CrCl <30 mL/min per
1.73 m2) were obtained.
Cox proportional hazards regression analysis was used
to estimate the hazard ratio (HR) mortality. Crude and
adjusted hazard ratios (HRs) with 95% confidence inter-
vals (CIs) were computed. Potential confounders associ-
ated with time to death in the univariable Cox regression
analysis were included in the multivariable Cox regression
model. Thus, in the final model, we adjusted for RI, age
diabetes mellitus, hypertension, previous myocardial in-
farction, treatment with glycoprotein IIb/IIIa receptor
blocker, Killip class and duration of procedure. All data
analyses were carried out using SPSS software version 20.
A two-sided P value <0.05 was considered significant.
Results
A total of 4,676 consecutive patients were treated with
primary PCI for STEMI or new onset LBBB MI at
Odense University Hospital between January 1, 2002 and
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for 83 patients, who were foreign citizens. Patients
undergoing a later acute MI after the first index proced-
ure (n = 223) were excluded. In 254 patients the creatinine
values were not available. Thus, the final study population
consisted of 4,116 patients; of these were 898 patients
diagnosed with RI, defined as CrCl < 60 mL/min per
1.73 m2, and 3,218 patients had a preserved kidney
function (Figure 1).
Baseline characteristics of patients with RI and pa-
tients with a preserved kidney function are listed in
Table 1. Patients with RI were older and more likely to
be female, to have diabetes, hypertension, previous MI,
hypercholesterolemia and less likely to be smokers.
Among patients with RI, patients with severe RI (CrCl <
30 mL/min per 1.73 m2) more often had diabetes. Char-
acteristics of angiographic findings, lesions and treatmentFigure 1 Flow diagram of participant selection.procedures also differed between patients with normal
and reduced CrCl, respectively. Patients with RI were
more likely to have multi-vessel disease, a higher Killip
class, left main culprit lesion, more complex lesions and
longer duration of procedure. Patients with RI were less
often treated with DES (Table 2).
The median follow-up interval was 3.3 years (25th –
75th percentile: 1.4-5.0 years), with a 1-year mortality of
10.7% (n = 441) and 5-year mortality of 17.2% (n = 707).
Among patients with a preserved kidney function and
patients with RI, 30-day all-cause mortality was 3.5%
(n = 112) and 20.9% (n = 188), respectively (log-rank
p < 0.001); 1-year all-cause mortality was 5.7% (n =
179) and 29.4% (n = 262), respectively (log-rank p <
0.001); 5-year all-cause mortality was 13.4% (n = 328)
and 47.4% (n = 379), respectively (log-rank p < 0.001).
Figure 2 shows the 5-year all-cause survival of the
Table 1 Baseline clinical characteristics according to kidney function
CrCl ≥ 60 Valid cases CrCl < 60 Valid cases P value (CrCl ≥ 60
vs. CrCl < 60)
CrCl ≤30 < 60 CrCl < 30 P value (CrCl < 30 vs.
CrCl ≤30 < 60)
Number of patients - no. 3,218 3,218 898 898 810 88
Male gender - no. (%) 2,486 (77.3) 3,218 524 (58.4) 898 <0.001 471 (58.1) 53 (60.2) 0.707
Age – (year) 61.5 ± 12.1 3,218 73.5 ± 11.0 898 <0.001 73.5 ± 10.8 72.8 ± 12.8 0.532
Family history - no. (%) 1,235 (39.8) 3103 194 (23.5) 824 <0.001 178 (23.8) 16 (20.8) 0.548
Smoking - no. (%) 1,712 (57.2) 2991 290 (39.1) 741 <0.001 257 (38.1) 33 (49.3) 0.075
Body Mass Index – (kg/m2) 26.8 (4.4) 2,132 26.6 (4.6) 507 0.256 26.7 (4.6) 24.9 (4.2) 0.009
Diabetes - no. (%) 272 (8.5) 3218 120 (13.4) 898 <0.001 101 (12.5) 19 (21.6) 0.017
Hypertension - no. (%) 930 (29.2) 3,180 404 (46.6) 867 <0.001 358 (45.8) 46 (54.1) 0.143
Previous coronary artery
bypass grafting - no. (%)
64 (2.0) 3,214 23 (2.6) 893 0.283 21 (2.6) 2 (2.3) 1.000
Previous percutaneous coronary
intervention - no. (%)
203 (6.4) 3,164 58 (6.7) 868 0.778 48 (6.1) 10 (11.8) 0.048
Previous myocardial
infarction - no. (%)
330 (10.4) 3,168 127 (14.5) 875 0.001 108 (13.7) 19 (13.7) 0.31
Lipid lowering therapy - no. (%) 617 (19.4) 3,173 201 (23.2) 866 0.015 173 (22.2) 28 (32.9) 0.025
Glycoprotein IIb/IIIa receptor
blocker – no. (%)
1,445 (48.2) 2,998 285 (34.4) 828 <0.001 263 (35.8) 22 (26.5) 0.110
Systolic blood pressure - (mmHg) 122.9 ±24.9 2,467 118.1 ±30.5 662 <0.001 118.7 ±30.3 112.4 ±32.0 0.118
Diastolic blood pressure - (mmHg) 71.8 ±13.9 2,449 66.0 ± 15.1 654 <0.001 66.4 ± 15.1 62.3 ± 15.9 0.043
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Table 2 Angiographic and procedural characteristics according to kidney function
CrCl ≥ 60 Valid cases CrCl < 60 Valid cases P value (CreaCl ≥ 60
vs. CreaCl < 60)
CrCl ≤30 < 60 CrCl < 30 P value (CrCl < 30
vs. CrCl ≤30 < 60)
Number of patients - no. 3,218 3,218 898 898 810 88
Multivessel disease no. (%) 1,304 (41.6) 3,135 520 (59.4) 876 <0.001 464 (58.7) 56 (65.9) 0.198
Infarct related artery –no. (%) 3,144 867 <0.001 0.230
Left anterior descending artery - no. (%) 1,383 (44.0) 340 (39.2) 314 (40.2) 26 (30.6)
Left circumflex artery - no. (%) 451 (14.3) 109 (12.6) 100 (12.6) 9 (10.6)
Right coronary artery - no. (%) 1,252 (39.8) 374 (43.1) 329 (42.1) 45 (52.9)
Left main - no. (%) 58 (1.8) 44 (5.1) 39 (5.0) 5 (5.9)
Anterior STEMI or LBBB – no. (%) 1,401 (45.2) 3,100 372 (43.1) 864 <0.001 343 (43.8) 29 (35.8) 0.100
Killip class – no. (%) 3,152 878 <0.001 0.001
I 2,925 (92.8) 676 (77.0) 624 (78.5) 52 (62.7)
II 135 (4.3) 62 (7.1) 55 (6.9) 7 (8.4)
III 51 (1.6) 51 (5.8) 46 (5.8) 5 (6.0)
IV 41 (1.3) 89 (10.1) 70 (8.8) 19 (22.9)
Preintervention TIMI flow – no. (%) 3,143 863 0.248 0.891
Grade 0 2,198 (54.2) 2,794 (58.7) 438 (56.2) 49 (59.9)
Grade 1 265 (6.5) 282 (5.9) 51 (6.5) 4 (4.8)
Grade 2 597 (14.7) 623 (13.1) 117 (15.0) 11 (13.3)
Grade 3 978 (24.1) 1,052 (22.1) 174 (22.3) 19 (22.9)
Final TIMI flow - no. (%) 3,143 863 <0.001 0.097
Grade 0 73 (2.3) 50 (5.8) 41 (5.3) 9 (10.8)
Grade 1 28 (0.9) 20 (2.3) 20 (2.6) 0 (0.0)
Grade 2 166 (5.3) 78 (9.0) 70 (9.0) 8 (9.6)
Grade 3 2,876 (91.5) 715 (82.9) 649 (83.2) 66 (79.5)
Lesion length – mm median (IQR) 15.00 (10.0-20.0) 3,110 15.0 (10.0-20.0) 855 0.676 15.00 (10.0-20.0) 15.00 (10.0-20.0) 0.318
Reference segment – mm median (IQR) 3.3 (3.0-3.6) 3,120 3.2 (3.0-3.5) 851 0.007 3.2 (3.0-3.5) 3.2 (2.8-3.5) 0.320
Minimum lumen diameter – mm median (IQR) 0.0 (0.0-0.2) 3,134 0.0 (0.0-0.2) 859 0.749 0.0 (0.0-0.2) 0.0 (0.0-0.2) 0.625
Sapheneous vein graft – no. (%) 10 (0.3) 3,145 4 (0.5) 867 0.526 2 (0.3) 2 (2.4) 0.007
Lesion type B2/C 1,012 (32.9) 3,082 338 (40.3) 838 <0.001 302 (39.7) 36 (46.2) 0.041
Stent length – mm median (IQR) 18.0 (14.0-23-0) 2,963 18.0 (14.0-24.0) 754 0.913 18.0 (14.0-24.0) 18.0 (13.0-24.0) 0.830
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Table 2 Angiographic and procedural characteristics according to kidney function (Continued)
Stent number - no. (%) 3,218 898 <0.001 0.007
0 255 (7.9) 144 (16.0) 120 (14.8) 24 (27.3)
1 2,578 (80.1) 643 (71.6) 591 (73.0) 52 (59.1)
2+ 385 (12.0) 111 (12.4) 99 (12.2) 12 (13.6)
Drug-eluting stent – no. (%) 1,962 (62.4) 3,146 366 (41.4) 885 <0.001 338 (42.3) 28 (32.6) 0.007
Max balloon pressure – atm median (IQR) 16.0 (14.0-18.0) 3,075 15.5 (14.0-17.3) 814 0.086 15.5 (14.0-17.0) 15.5 (14.0-18.0) 0.899
Max balloon diameter – mm median (IQR) 3.6 (3.2-3.8) 3,073 3.4 (3.2-3.8) 814 0.012 3.4 (3.2-3.8) 3.3 (3.0-3.7) 0.126
Duration of procedure - minutes median (IQR) 16.0 (10.0-26.0) 3,205 17.0 (11.0-28.0) 895 0.008 17.0 (11.0-28.0) 20.0 (12.0-30.8) 0.238
Flouro time - minutes median (IQR) 6.4 (4.0-11.2) 3,174 7.7 (4.5-13.0) 878 < 0.001 7.5 (4.4-13.0) 9.0 (6.0-13.3) 0.077
Contrast – ml median (IQR) 120.0 (75.0-180.0) 877 100.0 (75.0-175.0) 3,159 0.007 120.0 (75.0-185.0) 110.0 (80.0-174.0) 0.572
STEMI: ST-segment elevation myocardial infarct.
LBBB: new onset left bundle branch block.
IQR: Interquartile range.
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Figure 2 Kaplan-Meier curves for all-cause mortality in patients with CrCl < 60 mL/min per 1.73 m2 and CrCl ≥ 60 mL/min per 1.73 m2.
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CrCl < 60 mL/min per 1.73 m2 and CrCl ≥ 60 mL/min
per 1.73 m2 respectively.
Among patients with RI (group 1: CrCl <30 mL/min
per 1.73 m2 and group 2: CrCl ≤30 < 60 mL/min per
1.73 m2) the all-cause mortality rates were: at 30-day,
40.9% (n = 36) group 1 vs. 18.8% (n = 152) group 2 (log
rank p < 0.001); at 1-year, 57.5% (n = 50) group 1 vs.
26.4% (n = 212) group 2 (log rank p < 0.001) and at 5-
year, 71.3% (n = 58) group 1 and 44.8% (n = 321) group 2
(log rank p < 0.001). Figure 3 shows the 5-year all-cause
survival of STEMI patients when stratified into three
groups based on CrCl.
Table 3 shows the crude HR associated with 1-year
mortality. CrCl < 60 mL/min, diabetes, hypertension,
previous myocardial infarction and increasing Killip class
were associated with an increased mortality. Male gen-
der and treatment with glycoprotein IIb/IIIa receptor
blocker were associated with a lower mortality.
After adjustment for potential confounders (Table 3)
we found CrCl, diabetes, age, hypertension and Killip
class to be associated with increased 1-year mortality.
After adjustment for covariates associated with mortal-
ity, RI was associated with increased mortality at 30-day(adjusted HR 2.38, 95% CI 1.34-4.21), 1-year (adjusted
HR 2.29, 95% CI 1.50-3.50) and 5-year mortality (ad-
justed HR 2.02, 95% CI 1.50-2.72) compared to patients
with preserved kidney function.
Discussion
Based on an unselected cohort of STEMI patients this
study aimed to explore the impact of renal disease on
all-cause mortality among 4,116 STEMI patients treated
with primary PCI. In this real-world setting we found,
that RI was associated with increased short- and long-
term mortality. The strength of the present study is that
the patients are unselected, all-comer and consecutive.
Today guidelines suggest, that patients with STEMI and
renal dysfunction is treated in the same way as other
STEMI patients with the exception of administration of
contrast dye and some medications [11]. However, as
primary PCI in STEMI patients is an emergent therapy;
neither the kidney function nor the creatinine clearance
level will be known in these patients at the time of the
primary PCI. In our registry, most of the patients were
diagnosed prehospital in the ambulance and referred dir-
ectly to the catheterization laboratory, where the first
blood sample was collected from the arterial sheath
Figure 3 Kaplan-Meier curves for all-cause mortality in patients with CrCl <30 mL/min per 1.73 m2 vs. CrCl ≤30 < 60 mL/min per
1.73 m2 and CrCl ≥60 mL/min per 1.73 m2.
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showed from the Acute Coronary Treatment and Inter-
vention Outcome Network (ACTION) registry, that one
third of patients with STEMI had an eGFR < 60 mL/min
per 1.73 m2. This is a higher number than the 22% of
patients with RI we found in our study, which may be
related to the patient population, as patients in the AC-
TION registry had a different comorbidity risk, as the
rate of diabetes mellitus and hypertension were 2 to 3
times higher in the ACTION registry compared to our
registry data. In contrast to our study, Fox et al. de-
scribed that information about kidney function were
available to the treating physicians when therapeutic
decisions were made, and only 90% of patients with
STEMI received reperfusion therapy (80% as primary
PCI and 10% were treated with fibrinolysis). In our
study patients with RI were more likely to receive pri-
mary PCI without stent implantation and less likely to
receive treatment with glycoprotein IIb/IIIa receptor
blocker compared to patients without RI. Among 2,597
STEMI and non-STEMI patients Medi et al. [21] found,
that patients with RI and comorbidity were less likely toundergo coronary angiography, despite having the same
frequency of primary PCI treatment as non-RI patients
after angiography.
In our real-world setting registry we found, that RI
was associated with increased short- and long-term mor-
tality. This is in accordance with previous studies where
RI also has been found to be associated with a higher
30-days mortality and long term mortality [22-25].
Seyfarth et al. [26] found an increase in adjusted hazard
ratio after one year follow-up of 1.20 per 10-mL/min de-
crease in eGFR. In a study of Morel et al. [27] STEMI
and non-STEMI patients were found to have a higher 9-
month all-cause mortality when diagnosed with renal
disease. Sadeghi et al. [28] studied 1,933 patients from
the “Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC)”
trial, where baseline creatinine levels were obtained be-
fore angiography, including 350 patients with RI defined
as CrCl < 60 mL/min per 1.73 m2. In our registry cohort,
both short-term and 1-year mortality rate was more than
twice as high as in the study from Sadeghi et al. [28].
This difference is probably caused by (1) an increased
Table 3 crude and adjusted hazard ratio of covariates associated with 1-year mortality in Cox regression analysis
Valid cases Crude hazard
ratio (95% CI)
P value Adjusted hazard
ratio (95% CI)
P value
Male gender 4,116 0.68 (0.56-0.83) <0.001 1.11 (0.88-1.41) 0.354
Creatinine clearance 4,116 <0.001 <0.001
Creatinine clearance ≥ 60 mL/min Reference Reference
Creatinine clearance ≤30 < 60 mL/min 5.31 (4.35-6.49) 2.71 (2.09-3.51)
Creatinie clearance < 30 mL/min 15.37 (11.27-21.04) 7.09 (4.82-10.44)
Age – years 4,116 1.07 (1.06-1.08) <0.001 1.04 (1.03-1.06) <0.001
Diabetes mellitus 4,116 2.47 (1.95-3.13) <0.001 1.77 (1.33-2.35) <0.001
Hypertension 4,047 1.26 (1.03-1.53) 0.025 1.40 (1.11-1.76) 0.004
Previous myocardial infarction 4,043 1.99 (1.57-2.53) <0.001 1.53 (1.14-2.07) 0.006
Glycoprotein IIb/IIIa receptor blocker 3,826 0.49 (0.40-0.61) <0.001 0.68 (0.53-0.86) <0.001
Multivessel disease 4,011 2.32 (1.91-2.83) <0.001 1.15 (0.90-1.46) 0.265
Infarct related artery 4,011 <0.001 0.023
Right coronary artery Reference Reference
Left anterior descending artery 1.19 (0.96-1.48) 1.31 (1.03-1.68)
Left circumflex artery 1.02 (0.74-1.40) 1.24 (0.88-1.74)
Left main 4.02 (2.73-5.92) 1.92 (1.20-3.08)
Killip class 4,030 <0.001 <0.001
I Reference Reference
II 2.32 (1.64-3.30) 1.20 (1.20-2.69)
III 4.54 (3.17-6.51) 1.68 (1.68-3.79)
IV 9.55 (7.32-12.46) 1.86 (2.86-5.75)
Duration of procedure - minutes 4,100 1.01 (1.01-1.02) <0.001 1.01 (1.00-1.01) 0.007
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compared to results from a randomized controlled study
and (2) that patients with cardiogenic shock were not
excluded in our study. Bertomeu-Gonzales et al. [29]
studied the relationship between Killip class and impact
of renal disease on mortality and found, that renal dis-
ease was stronger associated with mortality in STEMI
patients with Killip I compared to patients with a higher
Killip class. In our study, patients with RI were more
likely to be older and female and they were more likely
to have diabetes, hyperlipidemia, and hypertension. The
finding of women representing a large proportion of
STEMI patients with RI is consistent with findings from
other studies [10,28,30,31]. RI was found to be an inde-
pendent predictor of 1-year mortality whereas we did
not find gender to be an independent risk factor for 1-
year mortality when adjusted for confounders. Similar
findings have been made by Damman et al. [32] where
3-year mortality was found to be associated with a de-
crease in renal function, whereas gender difference was
not proven to be a predictor of mortality after adjust-
ment for confounders.Limitations
The validity of our findings depends on data quality and
the ability to control for potential confounding. Like all
observational studies, our study is prone to biases re-
lated to unmeasured factors. Bias due to unknown vari-
ables cannot be eliminated. Patients with cardiogenic
shock were not excluded from the present study. We did
not have systematically access to creatinine values taken
in the following days after the primary PCI or informa-
tion about contrast-induced nephropathy. Patients with
RI were more often treated with balloon dilatation with-
out stent implantation or bare metal stent. One explan-
ation for this treatment strategy may be related to the
more common finding of severely calcified lesions,
which are known to limit complete DES expansion. We
also lacked data on causes of mortality, however, in a
previous STEMI cohort from Western Denmark Heart
Registry, we found that especially the early causes of
death was caused by a cardiac reason: the 1-year mortal-
ity reason was cardiac in 75% of the patients, whereas
the 3-year mortality reason is cardiac death in 60% of
the patients [33].
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In unselected STEMI patients treated with primary PCI,
RI was associated with increased short- and long-term
mortality compared to patients with a preserved kidney
function.
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